Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

423
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
423
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

545
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
545
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

2.7K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.7K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

466
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
466

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Machine learning differentiates right posterior from right anterior accessory pathways using 6-lead electrocardiograms in dogs with ventricular preexcitation.

Journal of the American Veterinary Medical Association·2025
Same author

Comparing Two-Dimensional Ellipsoid Model Variants in Estimating Three-Dimensional Echocardiographic Right Ventricular Volume in Dogs.

Journal of veterinary internal medicine·2025
Same author

Effect of additional dimensions and views in the echocardiographic determination of 3-dimensional left ventricular volume in myxomatous mitral valve disease in dogs.

Journal of veterinary internal medicine·2025
Same author

Electrocardiographic patterns of ventricular pre-excitation in dogs with right-sided accessory pathways.

Veterinary research communications·2023
Same author

Retrospective evaluation of hypertrophic cardiomyopathy in 68 dogs.

Journal of veterinary internal medicine·2022
Same author

Cardiac Disease of Raptors.

Journal of avian medicine and surgery·2022

Related Experiment Video

Updated: Feb 27, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K

Atrial Fibrillation: Current Therapies.

Romain Pariaut1

  • 1Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, 930 Campus Road, Ithaca, NY 14853-6401, USA.

The Veterinary Clinics of North America. Small Animal Practice
|June 25, 2017
PubMed
Summary

Managing atrial fibrillation in dogs involves rate control to slow heart rate using medications like diltiazem and digoxin, or rhythm control to restore normal sinus rhythm, often with electrical cardioversion.

Keywords:
AntiarrhythmicArrhythmiaCanineCardioversionTachycardia

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.2K
Robotic Ablation of Atrial Fibrillation
11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

20.3K

Related Experiment Videos

Last Updated: Feb 27, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.2K
Robotic Ablation of Atrial Fibrillation
11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

20.3K

Area of Science:

  • Veterinary Cardiology
  • Cardiac Electrophysiology

Background:

  • Atrial fibrillation management in canines requires distinct strategies.
  • Two primary approaches include rate control and rhythm control.

Purpose of the Study:

  • To outline the principles and common methods for managing atrial fibrillation in dogs.
  • To differentiate between rate and rhythm control strategies.

Main Methods:

  • Rate control involves limiting supraventricular impulses via the atrioventricular node.
  • Pharmacologic therapy for rate control typically combines diltiazem and digoxin.
  • Rhythm control utilizes pharmacologic or nonpharmacologic interventions to restore sinus rhythm.

Main Results:

  • Diltiazem and digoxin are frequently used for rate control in canine atrial fibrillation.
  • Transthoracic synchronized electrical cardioversion is a common method for rhythm control.

Conclusions:

  • Both rate and rhythm control strategies are viable for canine atrial fibrillation.
  • Treatment choice depends on clinical goals and patient status.